ADHD

Addiction & Substance Use

Anxiety & Stress Disorders

Bipolar Disorder

Bipolar I Disorder

COVID-19

Cannabis

Case Discussions

Comorbidity

Compulsive Disorders

Cultural Psychiatry

Depression

Digital Psychiatry

Digital Therapeutics

Eating Disorders

Ethics

Forensic Psychiatry

Impulse Control Disorder

Integrative Psychiatry

International Overdose Awareness

Major Depressive Disorder

Mental Health Systems

Mood Disorders

Neuropsychiatry

Pain

Personality Disorders

Psychedelics

Psychiatric Emergencies

Psychopharmacology

Psychosomatics

Psychotherapy

Schizophrenia/Psychosis

Sexual & Sexuality

Sleep Disorders

Special Populations

Suicide

Transcranial Magnetic Stimulation

News

Media

Around the Practice

Between the Lines

PsychView

Case-Based Psych Perspectives

Medical World News

Payer-Provider Perspective

Slideshows

Videos

Viewpoints

Webinars

Publications

Psychiatric Times

All Publications

Partner Perspectives

Job Board

CME/CE

Partners

Resources

Clinical Scales

Conference Coverage

Conference Listing

Interactive Tools

Quizzes

Series

Special Reports

Tipsheets

Toolkits

Subscribe

Print Subscription

eNewsletter

Articles

The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients. 

FDA Approves First Naloxone Product for Over-the-Counter Use

Aerobic exercise is a nonpharmacological intervention that has been shown to improve not only cardiovascular fitness, but also depressive symptoms, and cognition following traumatic brain injury.

Benefits of Aerobic Exercise Following Traumatic Brain Injury

March 30 is World Bipolar Day, a day dedicated to raising awareness and eliminating stigma surrounding bipolar disorders. Learn more about bipolar disorders by catching up on the latest bipolar research in Psychiatric Times®.

World Bipolar Day 2023

 is an award-winning psychiatrist who has specialized in the cultural and ethical aspects of psychiatry. A prolific writer and speaker, he received the one-time designation of Hero of Public Psychiatry from the Assembly of the American Psychiatric Association in 2002. To create a better world, he is an advocate for treating mental health issues related to climate instability, burnout, Islamophobia, and anti-Semitism. He serves on the Editorial Board of

Celebrating the life of Pedro Ruiz, MD…

There Will Be More Psychiatrist Eulogies Like This One on Pedro Ruiz, MD: Social Psychiatric Prediction #7

Advertise

Contact Us

Editorial

Terms and Conditions

Privacy Policy

Do Not Sell My Personal Information

Twitter

Facebook

LinkedIn

Spotlight

Expert Perspectives on the Clinical Management of Bipolar 1 Disorder

Expert Perspectives on the Unmet Needs in the Management of Major Depressive Disorder

Novel Delivery Systems Utilized in the Treatment of Adult ADHD

Commentary

Couch In Crisis

Early Career Psychiatry

History of Psychiatry

Residents Corner

Cultural Corner

Film and Book Reviews

Poetry

Writers Contest

Psychiatric Practice

Burnout

Careers

Coding

Guidelines

Risk Management

Telepsychiatry

Climate Change

Critical Conversations in Psychiatry

Portraits

Psychiatric Views on the Daily News

Tales From the Clinic: The Art of Psychiatry

Tales from the New Asylum

1rem

Authors

Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression. 

REL-1017: A New Treatment in the Works for Depression 

Maurizio Fava, MD

Articles